{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:51:25Z","timestamp":1792097485711,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K10121"],"award-info":[{"award-number":["21K10121"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K10121"],"award-info":[{"award-number":["21K10121"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K10121"],"award-info":[{"award-number":["21K10121"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K10121"],"award-info":[{"award-number":["21K10121"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K10121"],"award-info":[{"award-number":["21K10121"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02928-y","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:45:19Z","timestamp":1752140719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Epigenetic agents, zebularine and valproic acid, inhibit the growth of the oral squamous cell carcinoma cell line HSC4 in vitro and in vivo"],"prefix":"10.1007","volume":"16","author":[{"given":"Shuhei","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durga","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedy","family":"Ariwansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nagayasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Abiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"2928_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/bs.acc.2018.05.002","volume":"86","author":"Z Khurshid","year":"2018","unstructured":"Khurshid Z, Zafar MS, Khan RS, Najeeb S, Slowey PD, Rehman IU. Role of salivary biomarkers in oral cancer detection. Adv Clin Chem. 2018;86:23\u201370. https:\/\/doi.org\/10.1016\/bs.acc.2018.05.002.","journal-title":"Adv Clin Chem"},{"key":"2928_CR2","doi-asserted-by":"publisher","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma, Nat Rev Dis Primers 2020;6(1)92. https:\/\/doi.org\/10.1038\/s41572-020-00224-3","DOI":"10.1038\/s41572-020-00224-3"},{"key":"2928_CR3","doi-asserted-by":"publisher","unstructured":"Montero PH, Patel SG. Cancer of the oral cavity. Surg Oncol Clin N Am. 2015;24(3):491\u2013508. https:\/\/doi.org\/10.1016\/j.soc.2015.03.006.","DOI":"10.1016\/j.soc.2015.03.006"},{"key":"2928_CR4","doi-asserted-by":"publisher","unstructured":"Peters JM, Gonzalez FJ. The evolution of carcinogenesis. Toxicol Sci Off J Soc Toxicol. 2018;165(2):272\u20136. https:\/\/doi.org\/10.1093\/toxsci\/kfy184","DOI":"10.1093\/toxsci\/kfy184"},{"key":"2928_CR5","doi-asserted-by":"publisher","unstructured":"Nebbioso A, Tambaro FP, Dell\u2019Aversana C, Altucci L. Cancer epigenetics: moving forward. PLoS Genet. 2018;14(6):e1007362. https:\/\/doi.org\/10.1371\/journal.pgen.1007362.","DOI":"10.1371\/journal.pgen.1007362"},{"key":"2928_CR6","doi-asserted-by":"publisher","unstructured":"Ilango S, Paital B, Jayachandran P, Padma PR, Nirmaladevi R. Epigenetic alterations in cancer. Front Biosci Landmark Ed. 2020;25(6):1058\u20131109. https:\/\/doi.org\/10.2741\/4847","DOI":"10.2741\/4847"},{"key":"2928_CR7","doi-asserted-by":"publisher","unstructured":"Mummaneni P, Shord SS. Epigenetics and oncology. Pharmacotherapy. 2014;34(5):495\u2013505. https:\/\/doi.org\/10.1002\/phar.1408.","DOI":"10.1002\/phar.1408"},{"issue":"7","key":"2928_CR8","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.2174\/0929867327666200203113926","volume":"28","author":"E Pojani","year":"2021","unstructured":"Pojani E, Barlocco D. Romidepsin (FK228), a histone deacetylase inhibitor and its analogues in Cancer chemotherapy. Curr Med Chem. 2021;28(7):1290\u2013303. https:\/\/doi.org\/10.2174\/0929867327666200203113926.","journal-title":"Curr Med Chem"},{"key":"2928_CR9","doi-asserted-by":"publisher","unstructured":"Ramachandran S, Ient J, G\u00f6ttgens E-L, Krieg AJ, Hammond EM. Epigenetic therapy for solid tumors: highlighting the impact of tumor hypoxia. Genes 6(4):935\u201356. https:\/\/doi.org\/10.3390\/genes6040935","DOI":"10.3390\/genes6040935"},{"issue":"5","key":"2928_CR10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.4103\/jcrt.JCRT_403_17","volume":"15","author":"R Katarzyna","year":"2019","unstructured":"Katarzyna R, Lucyna B. Epigenetic therapies in patients with solid tumors: focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors. J Cancer Res Ther. 2019;15(5):961\u201370. https:\/\/doi.org\/10.4103\/jcrt.JCRT_403_17.","journal-title":"J Cancer Res Ther"},{"key":"2928_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/bs.acr.2016.01.007","volume":"130","author":"CA Zahnow","year":"2016","unstructured":"Zahnow CA, et al. Inhibitors of DNA methylation, histone deacetylation, and histone demethylation: A perfect combination for Cancer therapy. Adv Cancer Res. 2016;130:55\u2013111. https:\/\/doi.org\/10.1016\/bs.acr.2016.01.007.","journal-title":"Adv Cancer Res"},{"key":"2928_CR12","doi-asserted-by":"publisher","unstructured":"Lai J, et al. A drug-delivery depot for epigenetic modulation and enhanced cancer immunotherapy. Biomed Pharmacother. 2023;168:115687. https:\/\/doi.org\/10.1016\/j.biopha.2023.115687.","DOI":"10.1016\/j.biopha.2023.115687"},{"key":"2928_CR13","doi-asserted-by":"publisher","unstructured":"Kantarjian H et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 106(8):1794\u2013803. https:\/\/doi.org\/10.1002\/cncr.21792","DOI":"10.1002\/cncr.21792"},{"key":"2928_CR14","doi-asserted-by":"publisher","unstructured":"Di Costanzo A, Del Gaudio N, Migliaccio A, Altucci L. Epigenetic drugs against cancer: an evolving landscape. Arch Toxicol. 2014;88(9):1651\u201368. https:\/\/doi.org\/10.1007\/s00204-014-1315-6.","DOI":"10.1007\/s00204-014-1315-6"},{"key":"2928_CR15","doi-asserted-by":"publisher","unstructured":"Falchi L et al.  Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood 137(16):2161\u201370. https:\/\/doi.org\/10.1182\/blood.2020009004","DOI":"10.1182\/blood.2020009004"},{"key":"2928_CR16","doi-asserted-by":"publisher","unstructured":"Cheng JC et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst. 95(5):399\u2013409. 2003, https:\/\/doi.org\/10.1093\/jnci\/95.5.399","DOI":"10.1093\/jnci\/95.5.399"},{"key":"2928_CR17","doi-asserted-by":"publisher","unstructured":"Balagura G, Iapadre G, Verrotti A, Striano P. Moving beyond sodium valproate: choosing the right anti-epileptic drug in children. Expert Opin Pharmacother. 2019;20(12):1449\u201356. https:\/\/doi.org\/10.1080\/14656566.2019.1617850.","DOI":"10.1080\/14656566.2019.1617850"},{"issue":"10","key":"2928_CR18","doi-asserted-by":"publisher","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","volume":"17","author":"M Romoli","year":"2019","unstructured":"Romoli M, et al. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol. 2019;17(10):926\u201346. https:\/\/doi.org\/10.2174\/1570159X17666181227165722.","journal-title":"Curr Neuropharmacol"},{"key":"2928_CR19","doi-asserted-by":"publisher","unstructured":"Slingerland M, Guchelaar H-J, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors, Anticancer Drugs. 25(2):140\u20139. https:\/\/doi.org\/10.1097\/CAD.0000000000000040","DOI":"10.1097\/CAD.0000000000000040"},{"key":"2928_CR20","doi-asserted-by":"publisher","unstructured":"Sang Z, Sun Y, Ruan H, Cheng Y, Ding X, Yu Y. Anticancer effects of valproic acid on oral squamous cell carcinoma via SUMOylation in vivo and in vitro. Exp Ther Med. 12(6):3979\u201387. https:\/\/doi.org\/10.3892\/etm.2016.3907","DOI":"10.3892\/etm.2016.3907"},{"key":"2928_CR21","doi-asserted-by":"publisher","unstructured":"Kiyoshima T et al. Chemoresistance to concanamycin A1 in human oral squamous cell carcinoma is attenuated by an HDAC inhibitor partly via suppression of Bcl-2 expression. PLoS ONE. 8(11):e80998. https:\/\/doi.org\/10.1371\/journal.pone.0080998","DOI":"10.1371\/journal.pone.0080998"},{"key":"2928_CR22","doi-asserted-by":"publisher","unstructured":"Ren L, Lou Y, Sun M. The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) \/ receptor for advanced glycation end products (RAGE) pathway. Bioengineered. 2021;12(1):5985\u201395. https:\/\/doi.org\/10.1080\/21655979.2021.1972082","DOI":"10.1080\/21655979.2021.1972082"},{"key":"2928_CR23","doi-asserted-by":"publisher","unstructured":"Momose F, Araida T, Negishi A, Ichijo H, Shioda S, Sasaki S. Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 1989;18(7):391\u20135. https:\/\/doi.org\/10.1111\/j.1600-0714.1989.tb01570.x","DOI":"10.1111\/j.1600-0714.1989.tb01570.x"},{"issue":"1","key":"2928_CR24","doi-asserted-by":"publisher","first-page":"pp20","DOI":"10.11277\/stomatology1952.38.20","volume":"38","author":"K Takahashi","year":"1989","unstructured":"Takahashi K, et al. Establishment and characterization of a cell line (SAS) from poorly differentiated human squamous cell carcinoma of the tongue. J Jpn Stomatol Soc. 1989;38(1):20\u20138. https:\/\/doi.org\/10.11277\/stomatology1952.38.20. Jan. 1989.","journal-title":"J Jpn Stomatol Soc"},{"issue":"2","key":"2928_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999;4(2):67\u201373. https:\/\/doi.org\/10.1177\/108705719900400206.","journal-title":"J Biomol Screen"},{"key":"2928_CR26","doi-asserted-by":"publisher","unstructured":"Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621\u201381. https:\/\/doi.org\/10.1124\/pr.58.3.10","DOI":"10.1124\/pr.58.3.10"},{"key":"2928_CR27","doi-asserted-by":"publisher","unstructured":"Park HK, Han BR, Park WH. Combination of arsenic trioxide and valproic acid efficiently inhibits growth of lung cancer cells via G2\/M-phase arrest and apoptotic cell death. Int J Mol Sci. 2020;21(7):2649. https:\/\/doi.org\/10.3390\/ijms21072649.","DOI":"10.3390\/ijms21072649"},{"key":"2928_CR28","doi-asserted-by":"publisher","unstructured":"Hattori N, et al. Novel prodrugs of decitabine with greater metabolic stability and less toxicity. Clin Epigenet. 2019;11(1):111. https:\/\/doi.org\/10.1186\/s13148-019-0709-y.","DOI":"10.1186\/s13148-019-0709-y"},{"key":"2928_CR29","doi-asserted-by":"publisher","unstructured":"Castilho RM, Squarize CH, Almeida LO. Epigenetic modifications and head and neck cancer: implications for tumor progression and resistance to therapy. Int J Mol Sci. Jul. 2017;18(7):1506. https:\/\/doi.org\/10.3390\/ijms18071506.","DOI":"10.3390\/ijms18071506"},{"key":"2928_CR30","doi-asserted-by":"publisher","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif. 2001;25(4):402\u201308. https:\/\/doi.org\/10.1006\/meth.2001.1262","DOI":"10.1006\/meth.2001.1262"},{"key":"2928_CR31","doi-asserted-by":"publisher","unstructured":"Li L-C, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinforma Oxf Engl. 2002;18(11):1427\u201331. https:\/\/doi.org\/10.1093\/bioinformatics\/18.11.1427.","DOI":"10.1093\/bioinformatics\/18.11.1427"},{"key":"2928_CR32","doi-asserted-by":"publisher","unstructured":"Lu L, Katsaros D, de la Longrais IAR, Sochirca O, Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 2007;67(21):10117\u201310122. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2544","DOI":"10.1158\/0008-5472.CAN-07-2544"},{"key":"2928_CR33","doi-asserted-by":"publisher","unstructured":"Burkitt K, Saloura V. Epigenetic modifiers as novel therapeutic targets and a systematic review of clinical studies investigating epigenetic inhibitors in head and neck cancer. Cancers. 2021;13(20):5241. https:\/\/doi.org\/10.3390\/cancers13205241","DOI":"10.3390\/cancers13205241"},{"key":"2928_CR34","doi-asserted-by":"publisher","unstructured":"Nunes SP, Henrique R, Jer\u00f3nimo C, Paramio JM. DNA methylation as a therapeutic target for bladder cancer. Cells. 2020;9(8):1850. https:\/\/doi.org\/10.3390\/cells9081850","DOI":"10.3390\/cells9081850"},{"key":"2928_CR35","doi-asserted-by":"publisher","unstructured":"Caponigro F, et al. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and\/or metastatic squamous cell carcinoma of head and Neck-V-CHANCE trial. BMC Cancer. 2016;16(1):918. https:\/\/doi.org\/10.1186\/s12885-016-2957-y.","DOI":"10.1186\/s12885-016-2957-y"},{"key":"2928_CR36","doi-asserted-by":"publisher","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18(7):1414. https:\/\/doi.org\/10.3390\/ijms18071414.","DOI":"10.3390\/ijms18071414"},{"key":"2928_CR37","doi-asserted-by":"publisher","unstructured":"Soriano AO et al. Oct., Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110(7):2302\u20138. https:\/\/doi.org\/10.1182\/blood-2007-03-078576","DOI":"10.1182\/blood-2007-03-078576"},{"key":"2928_CR38","doi-asserted-by":"publisher","unstructured":"Raynal NJ-M, et al. Repositioning FDA-Approved drugs in combination with epigenetic drugs to reprogram colon cancer epigenome. Mol Cancer Ther. 2017;16(2):397\u2013407. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0588.","DOI":"10.1158\/1535-7163.MCT-16-0588"},{"key":"2928_CR39","doi-asserted-by":"publisher","unstructured":"Blagitko-Dorfs N et al. Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation. Leukemia. 2019;33(4):945\u201356. https:\/\/doi.org\/10.1038\/s41375-018-0293-8","DOI":"10.1038\/s41375-018-0293-8"},{"key":"2928_CR40","doi-asserted-by":"publisher","unstructured":"Napso T, Fares F. Zebularine induces prolonged apoptosis effects via the caspase-3\/PARP pathway in head and neck cancer cells. Int J Oncol. 2014;44(6):1971\u20139. https:\/\/doi.org\/10.3892\/ijo.2014.2386.","DOI":"10.3892\/ijo.2014.2386"},{"key":"2928_CR41","doi-asserted-by":"publisher","unstructured":"Gan CP et al. Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck. 2012;34(3):344\u201353. https:\/\/doi.org\/10.1002\/hed.21734","DOI":"10.1002\/hed.21734"},{"key":"2928_CR42","doi-asserted-by":"publisher","unstructured":"Rocco JW, Sidransky D. p16(MTS-1\/CDKN2\/INK4a) in cancer progression. Exp Cell Res. 2001;264(1):42\u201355. https:\/\/doi.org\/10.1006\/excr.2000.5149","DOI":"10.1006\/excr.2000.5149"},{"key":"2928_CR43","doi-asserted-by":"publisher","unstructured":"Chen S, et al. LincRNa-p21: function and mechanism in cancer. Med Oncol Northwood Lond Engl. 2017;34(5):98. https:\/\/doi.org\/10.1007\/s12032-017-0959-5.","DOI":"10.1007\/s12032-017-0959-5"},{"key":"2928_CR44","doi-asserted-by":"publisher","unstructured":"DeMorrow S, et al. Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion. Am J Physiol Cell Physiol. 2011;300(5):C1078\u20131089. https:\/\/doi.org\/10.1152\/ajpcell.00358.2010.","DOI":"10.1152\/ajpcell.00358.2010"},{"issue":"7","key":"2928_CR45","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.7150\/ijbs.41587","volume":"16","author":"Y Bai","year":"2020","unstructured":"Bai Y, et al. Development and validation of a prognostic nomogram for gastric Cancer based on DNA methylation-driven differentially expressed genes. Int J Biol Sci. 2020;16(7):1153\u201365. https:\/\/doi.org\/10.7150\/ijbs.41587.","journal-title":"Int J Biol Sci"},{"key":"2928_CR46","doi-asserted-by":"publisher","unstructured":"Ushio R, Hiroi M, Matsumoto A, Mori K, Yamamoto N, Ohmori Y. Enhanced cytotoxic effects in human oral squamous cell carcinoma cells treated with combined methyltransferase inhibitors and histone deacetylase inhibitors. Biomedicines. 2022;10(4):763. https:\/\/doi.org\/10.3390\/biomedicines10040763","DOI":"10.3390\/biomedicines10040763"},{"key":"2928_CR47","doi-asserted-by":"publisher","first-page":"874706","DOI":"10.3389\/fimmu.2022.874706","volume":"13","author":"MA Whitmore","year":"2022","unstructured":"Whitmore MA, Li H, Lyu W, Khanam S, Zhang G. Epigenetic regulation of host defense peptide synthesis: synergy between histone deacetylase inhibitors and DNA\/histone methyltransferase inhibitors. Front Immunol. 2022;13:874706. https:\/\/doi.org\/10.3389\/fimmu.2022.874706.","journal-title":"Front Immunol"},{"key":"2928_CR48","doi-asserted-by":"publisher","unstructured":"Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38(1):23\u201338. https:\/\/doi.org\/10.1038\/npp.2012.112.","DOI":"10.1038\/npp.2012.112"},{"key":"2928_CR49","doi-asserted-by":"publisher","unstructured":"Linnekamp JF, Butter R, Spijker R, Medema JP, van Laarhoven HWM. Clinical and biological effects of demethylating agents on solid tumours\u2014a systematic review. Cancer Treat. Rev. 2017;54:10\u201323. https:\/\/doi.org\/10.1016\/j.ctrv.2017.01.004","DOI":"10.1016\/j.ctrv.2017.01.004"},{"key":"2928_CR50","doi-asserted-by":"publisher","unstructured":"Bayat Mokhtari R, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022\u201343. https:\/\/doi.org\/10.18632\/oncotarget.16723.","DOI":"10.18632\/oncotarget.16723"},{"key":"2928_CR51","doi-asserted-by":"publisher","unstructured":"Ocker M, Bitar SA, Monteiro AC, Gali-Muhtasib H, Schneider-Stock R. Epigenetic regulation of p21cip1\/waf1 in human cancer. Cancers. 2019;11(9):1343. https:\/\/doi.org\/10.3390\/cancers11091343.","DOI":"10.3390\/cancers11091343"},{"key":"2928_CR52","doi-asserted-by":"publisher","unstructured":"Sergeeva A, Davydova K, Perenkov A, Vedunova M. Mechanisms of human DNA methylation, alteration of methylation patterns in physiological processes and oncology. Gene. 2023;875:147487. https:\/\/doi.org\/10.1016\/j.gene.2023.147487.","DOI":"10.1016\/j.gene.2023.147487"},{"key":"2928_CR53","doi-asserted-by":"publisher","unstructured":"Young CS, Clarke KM, Kettyle LM, Thompson A, Mills KI. Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy. Oncotarget. 2017;8(31):51429\u201346. https:\/\/doi.org\/10.18632\/oncotarget.18009","DOI":"10.18632\/oncotarget.18009"},{"issue":"3","key":"2928_CR54","doi-asserted-by":"publisher","first-page":"e0120545","DOI":"10.1371\/journal.pone.0120545","volume":"10","author":"K Nakamura","year":"2015","unstructured":"Nakamura K, et al. DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status. PLoS ONE. 2015;10(3):e0120545. https:\/\/doi.org\/10.1371\/journal.pone.0120545.","journal-title":"PLoS ONE"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02928-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:45:21Z","timestamp":1752140721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02928-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2928"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02928-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments in this study were approved by the animal ethics and research committee of Health Sciences University of Hokkaido (Approval No.: 018 in 2020) and were conducted in accordance with the Basel Declaration and The ARRIVE guidelines. The maximal tumor size permitted by our ethics committee was 20\u00a0mm in diameter or 10% of body weight, in accordance with internationally accepted animal welfare standards, and this limit was not exceeded during the experimental period.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and accordance"}},{"value":"Not applicable to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The initial version of this manuscript was proofread by a professional English editing service. During the revision process after peer review, ChatGPT-4o (OpenAI) was used exclusively to assist with grammar correction and language refinement in the newly added or revised sections. No AI tools were used to generate scientific content or interpret findings.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of artificial intelligence tools"}}],"article-number":"1293"}}